If this message does not appear correctly, click this link


Speeches & Conferences

May 28  HK patient education forum- using genomic profiling services for effective cancer treatment

To share the latest trend in cancer treatment, ACT Genomics Hong Kong cooperates with the largest cancer information sharing platform-cancer information.com.hk to organize a patient education forum in Hong Kong Central Library on May 28th. The guest speaker, Dr. Amy Chang will tell the audience how to find the most effective cancer treatment.

Image title


May 16   NGS-guided medical seminar at Gleneagles hospital

Next generation sequencing is a new option in cancer treatment but it is not almighty. In the medical seminar held by University of Hong Kong (HKU) and Gleneagles hospital and sponsored by ACT Genomics, Prof. Ngan, KC Roger and Dr. Lam, Tai Chung from Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, the University of Hong Kong will share successful NGS cases and walk oncologists through the journey of using NGS-guided cancer treatment properly.

Image title


May 16   ACT Genomics Scientific Talk at Sarawak General Hospital

ACT Genomics is honoured to be invited to give a scientific talk at Sarawak General Hospital in Malaysia.  Dr. Liisa will be sharing  with the oncologists & medical officers: The Role of Comprehensive Genomic Profiling in Cancer Management in the Era of Precision Medicine.


May 09   Meet ACT Genomics Hong Kong in HK International medical device event

One of the important events, Hong Kong International Medical Device and Supplies Fair 2018, is held from May 7 th-9 th.  Dr. Timothy Yip elaborated on  how Next Generation Sequencing can lead to personalized cancer treatment on May 9 th. ACT Genomics Hong Kong provided more cancer genomic profiling services information in G22 display area.

Image title


May 08   HK patient education forum-treating lung cancer from genetic and psychological aspects

To bring hope and warmth to lung cancer patients, ACT Genomics Hong Kong cooperated with the well-known healthcare magazine, HEALTH ACTION, in Hong Kong to organize a patient education forum in Hong Kong Cultural Centre on May 8 th. The guest speakers, Dr. Shih and Dr. Ho told the audience how to treat lung cancer precisely through genomic profiling services and how positive attitude toward disease can fight cancer effectively.

Image title


May 05-06  Novel treatment strategies in precision cancer medicine in TJCC

The most influential annual event in cancer treatment in Taiwan, the 23rd Taiwan Joint Cancer Conference (TJCC) was held at Taipei Marriot Hotel from 5th-6th May. ACT Genomics invited the Deputy Director of Tokyo Medical and Dental University Cancer Center, Dr. Sadakatsu Ikeda as guest speaker and the Director of National Taiwan Hospital Graduate Institute of Oncology, Dr. James Chih-Hsin Yang as moderator, to share insights on novel treatment strategies in precision cancer medicine on 5thMay. Novel treatment strategies, such as immune therapy and combination therapy of molecular targeted agents, are emerging to overcome the limited duration of response in common monotherapy treatment strategy. ACT Genomics introduced how cancer genomic profiling services can assist the novel cancer treatment strategies in A29 display area.

Image title


May 03  ACT Genomics predicts the future of diagnosis in Singapore

Dr. Allen is honoured to be invited to join the Industry Roundtable Series by NUS Enterprise discussing on Next Generation Sequencing: The Future of Diagnostics. https://www.eventnook.com/event/nusenterprise-futurehealth

Image title


Apr 25  ACT Genomics Scientific Talk at Siriraj Hospital

ACT Genomics is honoured to be invited to give a scientific talk at Siriraj Hospital in Thailand. Dr. Poon shared the challenges & promises of comprehensive genomic profiling and biomarkers in cancer immunotherapy.



Apr 19   ACT Genomics Scientific Talk at Cipto Mangunkusumo General Hospital

ACT Genomics is honoured to be invited to give a scientific talk at Cipto Mangunkusumo General Hospital, Jakarta. Dr. Liisa shared on the topic: Can Next Generation Sequencing fulfill its promises in cancer management in the era of precision medicine?



Apr 15   ACT Genomics Hong Kong shared hereditary cancer information in Macau

ACT Genomics Hong Kong is honoured to be invited to give a scientific talk at Associação de Profissionais de Medicina Chinesa de Macau. Dr. Timothy Yip, ACT Genomics representative and Dr. Joseph Siu-Kie Au, Specialist in Clinical Oncology, Hong Kong Adventist Hospital shared topics on hereditary cancer to many oncologists and government officials.

Image title


Apr 06   ACT Genomics visited University of Macau for future cooperation

ACT Genomics visited University of Macau and learned about their current findings in zebrafish gonad development and single-cell dynamics lectured by Prof. Chung Bon-Chu and Prof. Chen Sheng-Hong at University of Macau.  To faciliate knowledge sharing on cancer genomics with University of Macau, ACT Genomics discussed future collaboration opportunities with Prof. Deng Chu-Xia, Dean of Faculty of Health Sciences at University of Macao.

Image title

Media


May 01  Using genomic profiling services to optimize late-stage cancer treatment

Late stage, metastatic, or rare cancers are often considered difficult to treat. ACT Genomics shared experiences in the Taiwan leading healthcare magazine on how to select appropriate drugs among multiple options to decrease side-effect and optimize the treatment results via genomic profiling services.

Image title


Apr 11  The new biomedical winner in Southeast Asia

Dr. Allen Lai is honoured to be featured in Taiwan Trade Insight magazine, sharing his insight and vision on comprehensive genomic profiling in Southeast Asia market.

Online version: http://www.trademag.org.tw/content02.asp?id=724060&type=50&url=%2Findex%2Easp%3Fno%3D50

Hard copy version:  https://drive.google.com/file/d/1X0_9vLp4aIxhPPTBE0inEF0mwfJez5N4/view

Image title


Apr 10  Hundreds of biomedical companies join forces to form MDXIAT

ACT Genomics and more than one hundred biotech companies formed Precision Medicine & Molecular Diagnostics Industry Association in Taiwan (MDXIAT). Besides Taiwan Bio Industry Organization (TBIO), Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), MDXIAT is the third association related to innovative biotechnology in Taiwan. ACT Genomics CEO, Dr. Hua-Chien Chen is honoured to be one of the first board of directors in MDXIAT. https://udn.com/news/story/7241/3079250 

Image title

Image title

The Cancer Genome Atlas published the latest study results of the pan-cancer molecular features

Abstract : The Cancer Genome Atlas (TCGA) analyzed the molecular information and the clinical data from more than 10,000 tumors across 33 types of cancers. These findings described the new molecular characteristics of subtypes in pan-cancer, which could serve as a basis to develop new treatment strategies.   See more...


Image title

The new combination therapy showed clinical benefit for BRAF-mutant melanoma

Abstract : In a randomized phase III trial (COLUMBUS), patients with BRAF V600E or BRAF V600K advanced, unresectable or metastatic melanoma were treated with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib to identify its clinical activity. The results demonstrated that the new combination therapy has potential as a new treatment option in patients with BRAF-mutant melanoma.  See more...


Image title

Osimertinib poised to be first-line standard of care in advanced EGFR mutation-positive NSCLC

Abstract : In a phase III trial (FLAURA), advanced NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation) were treated with osimertinib. The results suggested that osimertinib could be a suitable first-line treatment for advanced EGFR mutation-positive NSCLC patients in the future.  See more...


Image title

FDA accepted the regulatory submissions for review of a new second-generation EGFR inhibitor in first-line NSCLC

Abstract : The FDA accepted the regulatory submissions for review of dacomitinib for first-line treatment of patients with NSCLC. The submissions are based on a randomized phase III trial (ARCHER 1050). In this trial, patients with EGFR-mutated (exon 19 deletion or L858R mutation) NSCLC were treated with dacomitinib. The positive results revealed that dacomitinib could be a new treatment option for patients with EGFR-mutated NSCLC.  See more...


Image title

Pathogenic germline variants were identified in 8% cancer patients in latest study

Abstract : A large integrated investigation of suspected variants in cancer patients was conducted, including 10,389 adult cases from 33 cancer types. The results provide future principles of hereditary variant classification and genetic testing in cancer patients. See more...

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :